| |
Friendly
Pig Crop Report,
But Keep an Eye On Litter Size
Friday’s quarterly Hogs and Pigs Report contained few
surprises, but a few interesting numbers that should be carefully noted
as producers make plans for the coming months. See Table 1 for data.
The key number for short-term markets is a market herd at 58.612 million
head or 96.3% of one year ago. That is not a small market herd by any
stretch. In fact, it is the third-largest ever for a June 1 count. The
only two larger were in 2008 (61.27 million) and 2009 (60.842 million).
This relationship underscores the fact that we almost need to put any of
these all-time records in a pre-porcine circovirus (PCV) vaccine and
post-PCV vaccine context. While PCV vaccine is not the only driver of
higher numbers, it is definitely a major one and the only one that we
can track to a particular point in time.
FULL ARTICLE
|
Postweaning “Fading Pig/Anorexia Syndrome”
Found in pigs worldwide, Hemagglutinating
Encephalomyelitis Virus (HEV) infection has been largely ignored for
decades, but the disease is still present and causes clinical problems.
HEV was first linked to neurological disease in baby pigs in Ontario,
Canada in 1962. Shortly thereafter, it was also identified as the cause
of a postweaning syndrome of anorexia, lethargy and depression that was
called Vomiting and Wasting Disease.
HEV is an RNA virus. HEV is a serologic Group 2 coronavirus different
from the serologic Group 1 coronaviruses that include Transmissible
gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV).
Bovine coronavirus is more closely related to HEV. HEV only infects
pigs.
Researchers at different institutions have been able to reproduce both
clinical syndromes by experimentally infecting pigs with HEV. HEV
replicates in the nasal cavity and tonsils and is also subsequently
found in lung, stomach and small intestine. HEV is thought to spread to
the brain through sensory nerves. Inflammation of nerves in the stomach
is associated with the Vomiting and Wasting Disease in postweaning
pigs.
FULL ARTICLE
|
EPA
Delays E15 Rule
The Environmental Protection Agency announced it would
delay until fall a decision on whether to increase the blend rate for
ethanol above the current 10% limit. In a statement, EPA said more
testing still needs to be conducted on cars to how they perform on a 15%
ethanol blend. EPA said the ‘preliminary results “look good.”
Growth Energy said, “As you would expect, we find this further delay
unacceptable. The fact that the federal agencies involved here cannot
meet their own deadlines – on a decision that means so much to our
nation – reinforces a public perception that government bureaucracy
does not work in the best interests of the public. With fossil fuels
getting dirtier, costlier and riskier to extract, as we are witnessing
with the epic catastrophe in the Gulf of Mexico, now is the time we
should move on expanding the production and consumption of clean,
renewable fuels like ethanol.” Growth Energy filed the petition last
year requesting the increase to 15% blend.
Roadmap to Achieve Renewable Energy Goals — USDA released a
report outlining the current state of renewable transportation fuels
efforts and a plan to develop regional strategies to increase the
production, marketing, and distribution of fuels in the United States.
The report, “A USDA Regional Roadmap to Meeting the Biofuels Goals of
the Renewable Fuels Standard by 2022,” provides information on current
production and consumption patterns and projections to meet the RFS
mandate of 36 billion gallons of biofuels by 2022. USDA's report
identifies numerous biomass feedstocks to be utilized in developing
biofuels and calls for the funding of further investments in research
and development of:
FULL ARTICLE
|
Canada
Passes Free Trade Agreement with Columbia
The Canadian Senate has given final approval to a free
trade agreement (FTA) with Columbia, providing immediate market access
for Canadian pork and pork products and placing the United States at a
distinct trade disadvantage.
Back in late 2006, more than three and a half years ago, the United
States and Columbia signed a free trade agreement. The Columbian Senate
in 2007 voted to approve the agreement by a margin of 55-3 and the House
by a margin of 85-10. The U.S. Congress, however, has not yet begun
debate on the implementing legislation.
Iowa State University agricultural economist Dermot Hayes says the
U.S.-Columbia FTA, when fully implemented, would raise U.S. live hog
prices by $1.15/head. He says if the United States does not implement
its FTA with Columbia, within 10 years the country will be completely
shut out of the Columbian pork market because of Canada’s FTA tariff
advantage.
FULL ARTICLE
|
July 18-21, 2010: 21st International Pig
Veterinary Society Congress, Vancouver Convention and Exhibition Centre,
Vancouver, British Columbia, Canada;
For more information
contact: (604) 688-9655 ext. 2 or ipvs2010@advance-group.com
or go to http://www.ipvs2010.com/.
August 31, 2010: 20th Annual Carthage Veterinary
Service, Ltd. Swine Conference, Western Illinois University
Macomb,
IL
For more information contact: (217) 357-2811 or go to www.hogvet.com.
September 18-21, 2010: Allen D. Leman Swine
Conference, RiverCentre
St. Paul, MN
For more information
contact: (765)-463-3594 or www.cvm.edu/VetMedCE.
FULL ARTICLE
|
|
|
advertisement
NPPC conducts public-policy outreach on behalf of its 43 state
associations, enhancing opportunities for the success of U.S. pork
producers and stakeholders by establishing the pork industry as a
consistent and responsible supplier of high-quality pork to domestic and
world markets. Click here to learn
more and support your industry.
|
BLUEPRINT
advertisement
MAGAZINE HIGHLIGHTS
advertisement
POSTERS
SUBSCRIBER TOOLS
advertisement
According to a head-to-head trial1,
LINCOMIX® (lincomycin) is equally as efficacious for
ileitis control at 40 g/T as Tylan® is at 100 g/T. That
means you’ll spend a whopping 40% less for comparable results. Contact
your veterinarian or your Pfizer Animal Health representative to learn
more.
1. Data on file, Study Report No. 768-9690-0-CPC-97-002, Pfizer
Inc.
|
|
|
